Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis
Aim. To investigate the effect of ABCB1 gene carriage and interdrug interactions on apixaban pharmacokinetics and clinical outcomes in patients with atrial fibrillation and deep vein thrombosis.Material and methods. Patients hospitalized at Yudin State Clinical Hospital participated in the study. A...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2023-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2848 |
| _version_ | 1826949514043326464 |
|---|---|
| author | L. V. Fedina I. N. Sychev T. D. Rastvorova E. V. Strigunkova A. A. Kachanova Z. A. Sozaeva P. O. Bochkov A. V. Vardanyan K. B. Mirzayev D. A. Sychev |
| author_facet | L. V. Fedina I. N. Sychev T. D. Rastvorova E. V. Strigunkova A. A. Kachanova Z. A. Sozaeva P. O. Bochkov A. V. Vardanyan K. B. Mirzayev D. A. Sychev |
| author_sort | L. V. Fedina |
| collection | DOAJ |
| description | Aim. To investigate the effect of ABCB1 gene carriage and interdrug interactions on apixaban pharmacokinetics and clinical outcomes in patients with atrial fibrillation and deep vein thrombosis.Material and methods. Patients hospitalized at Yudin State Clinical Hospital participated in the study. A total of 92 patients (50 patients received apixaban and 42 – rivaroxaban) with non-valvular atrial fibrillation and deep vein thrombosis were included. Genotyping was performed by real-time polymerase chain reaction. Direct oral anticoagulants concentrations were measured using an electrospray ionization mass spectrometer in positive ionization mode.Results. In our study we found that in patients carrying the CT+TT ABCB1 (rs4148738) C>T genotype encoding the carrier protein (P-gp), the plasma concentration of rivaroxaban was statistically significantly higher p= 0.026. In addition, we found that patients taking apixaban together with a CYP3A4/P-gp inhibitor were 3.5 times more likely to have hemorrhagic complications than those without inhibitors p = 0.004.Conclusion. Our study revealed that the plasma concentration of rivaroxaban was higher in patients carrying the ABCB1 (rs4148738) C>T polymorphism T allele. And patients taking apixaban together with CYP3A4/P-gp inhibitor had higher risk of hemorrhagic complications in comparison with patients not taking such drugs. Further studies are needed on the influence of pharmacogenetics and pharmacokinetics on the safety and efficacy profile of apixaban and rivaroxaban, taking into account the trend of systemic approach to optimization of anticoagulant therapy of direct oral anticoagulants based on pharmacokinetic, pharmacogenetic biomarkers. |
| first_indexed | 2024-03-08T14:00:02Z |
| format | Article |
| id | doaj.art-547d7b56152449b99e64946f0dcd6d76 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2025-02-17T22:14:30Z |
| publishDate | 2023-01-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-547d7b56152449b99e64946f0dcd6d762024-12-04T11:48:21ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532023-01-0118662462910.20996/1819-6446-2022-12-022074Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein ThrombosisL. V. Fedina0I. N. Sychev1T. D. Rastvorova2E. V. Strigunkova3A. A. Kachanova4Z. A. Sozaeva5P. O. Bochkov6A. V. Vardanyan7K. B. Mirzayev8D. A. Sychev9Russian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationAim. To investigate the effect of ABCB1 gene carriage and interdrug interactions on apixaban pharmacokinetics and clinical outcomes in patients with atrial fibrillation and deep vein thrombosis.Material and methods. Patients hospitalized at Yudin State Clinical Hospital participated in the study. A total of 92 patients (50 patients received apixaban and 42 – rivaroxaban) with non-valvular atrial fibrillation and deep vein thrombosis were included. Genotyping was performed by real-time polymerase chain reaction. Direct oral anticoagulants concentrations were measured using an electrospray ionization mass spectrometer in positive ionization mode.Results. In our study we found that in patients carrying the CT+TT ABCB1 (rs4148738) C>T genotype encoding the carrier protein (P-gp), the plasma concentration of rivaroxaban was statistically significantly higher p= 0.026. In addition, we found that patients taking apixaban together with a CYP3A4/P-gp inhibitor were 3.5 times more likely to have hemorrhagic complications than those without inhibitors p = 0.004.Conclusion. Our study revealed that the plasma concentration of rivaroxaban was higher in patients carrying the ABCB1 (rs4148738) C>T polymorphism T allele. And patients taking apixaban together with CYP3A4/P-gp inhibitor had higher risk of hemorrhagic complications in comparison with patients not taking such drugs. Further studies are needed on the influence of pharmacogenetics and pharmacokinetics on the safety and efficacy profile of apixaban and rivaroxaban, taking into account the trend of systemic approach to optimization of anticoagulant therapy of direct oral anticoagulants based on pharmacokinetic, pharmacogenetic biomarkers.https://www.rpcardio.online/jour/article/view/2848doacpharmacogeneticsabcb1drug interactionsapixabanrivaroxaban |
| spellingShingle | L. V. Fedina I. N. Sychev T. D. Rastvorova E. V. Strigunkova A. A. Kachanova Z. A. Sozaeva P. O. Bochkov A. V. Vardanyan K. B. Mirzayev D. A. Sychev Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis Рациональная фармакотерапия в кардиологии doac pharmacogenetics abcb1 drug interactions apixaban rivaroxaban |
| title | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis |
| title_full | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis |
| title_fullStr | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis |
| title_full_unstemmed | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis |
| title_short | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis |
| title_sort | effect of abcb1 gene carriage and drug drug interactions on apixaban and rivaroxaban pharmacokinetics and clinical outcomes in patients with atrial fibrillation and deep vein thrombosis |
| topic | doac pharmacogenetics abcb1 drug interactions apixaban rivaroxaban |
| url | https://www.rpcardio.online/jour/article/view/2848 |
| work_keys_str_mv | AT lvfedina effectofabcb1genecarriageanddrugdruginteractionsonapixabanandrivaroxabanpharmacokineticsandclinicaloutcomesinpatientswithatrialfibrillationanddeepveinthrombosis AT insychev effectofabcb1genecarriageanddrugdruginteractionsonapixabanandrivaroxabanpharmacokineticsandclinicaloutcomesinpatientswithatrialfibrillationanddeepveinthrombosis AT tdrastvorova effectofabcb1genecarriageanddrugdruginteractionsonapixabanandrivaroxabanpharmacokineticsandclinicaloutcomesinpatientswithatrialfibrillationanddeepveinthrombosis AT evstrigunkova effectofabcb1genecarriageanddrugdruginteractionsonapixabanandrivaroxabanpharmacokineticsandclinicaloutcomesinpatientswithatrialfibrillationanddeepveinthrombosis AT aakachanova effectofabcb1genecarriageanddrugdruginteractionsonapixabanandrivaroxabanpharmacokineticsandclinicaloutcomesinpatientswithatrialfibrillationanddeepveinthrombosis AT zasozaeva effectofabcb1genecarriageanddrugdruginteractionsonapixabanandrivaroxabanpharmacokineticsandclinicaloutcomesinpatientswithatrialfibrillationanddeepveinthrombosis AT pobochkov effectofabcb1genecarriageanddrugdruginteractionsonapixabanandrivaroxabanpharmacokineticsandclinicaloutcomesinpatientswithatrialfibrillationanddeepveinthrombosis AT avvardanyan effectofabcb1genecarriageanddrugdruginteractionsonapixabanandrivaroxabanpharmacokineticsandclinicaloutcomesinpatientswithatrialfibrillationanddeepveinthrombosis AT kbmirzayev effectofabcb1genecarriageanddrugdruginteractionsonapixabanandrivaroxabanpharmacokineticsandclinicaloutcomesinpatientswithatrialfibrillationanddeepveinthrombosis AT dasychev effectofabcb1genecarriageanddrugdruginteractionsonapixabanandrivaroxabanpharmacokineticsandclinicaloutcomesinpatientswithatrialfibrillationanddeepveinthrombosis |